Pyr mispairs are processed with reduced efficiency. The C-C mismatch is the weakest substrate, repaired in some sequence contexts but not others (5, 6, 8) . ID heterologies of 1-5 nucleotides are subject to nick-directed correction with efficiencies comparable with those of Pur-Pyr and Pur-Pur mispairs (8, 10, 11) . The upper limit on ID heterology size for correction by the mismatch repair system appears to lie between 8 and 12 nucleotides, with larger heterologies processed by a distinct system (10) . 3 The mechanism of nick-directed mismatch repair, deduced from study of the reaction in human nuclear extracts, is shown in Fig. 1 . The strand break that directs correction can be located either 3Ј or 5Ј to the mispair, with mismatch-provoked excision removing that portion of the incised strand spanning the two DNA sites (7) . This mechanism is largely based on study of the fate of nicked heteroduplex DNA in nuclear extracts under conditions of repair DNA synthesis inhibition by aphidicolin (5, 6) or by omission of exogenous dNTPs (7) . Mismatch-free, nicked homoduplex DNA is ligated under these conditions, but heteroduplex molecules are subject to mismatch-provoked excision to yield a gap extending from the site of the strand break and terminating at a number of discrete sites 90 -170 nucleotides beyond the original location of the mispair. This scheme is also consistent with the location of repair DNA synthesis tracts visualized by incorporation of radiolabeled nucleotides (5, 6) or by mapping incorporated ␣-thionucleotides when dCTP was partially substituted with dCTP␣S (12) . Since the repaired DNA strand is recovered from nuclear extracts largely as a full-length, covalently continuous species (7) , the last step of the reaction presumably involves ligase closure of the strand break that remains after repair synthesis.
The nature of the excision step in the human repair reaction has not been established, but the mechanism of the overall reaction shown in Fig. 1 is similar to that of E. coli methyl-directed mismatch correction, in which excision is exonucleolytic and initiates at the strand break (4). 1 Since each of the base-base mismatches and a dinucleotide ID mispair provoke a similar gap formation reaction in human cell extracts (7, 8) , nick-directed repair of these different heterologies has been attributed to a single pathway. This broad mismatch specificity is similar to that of the bacterial methyl-directed system.
Human MutS and MutL Homologs in Strand-specific
Mismatch Repair Initiation of bacterial mismatch repair occurs via mismatch recognition by a MutS homodimer followed by binding of MutL, with the latter protein probably serving to interface mismatch recognition by MutS to other components of the repair system (4, 13). 1 Human mismatch repair has not been reconstituted in a defined system, but five activities have been implicated in the reaction, including several that are structural and functional homologs of MutS and MutL.
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‡ To whom correspondence should be addressed. mutable cell lines resistant to the cytotoxic action of certain DNAdamaging agents, are defective in nick-directed mismatch repair. These cell lines define several in vitro complementation groups (9, 11) , and activities that restore repair to extracts of two of these have been isolated. Human MutS␣, a heterodimer of the MutS homologs MSH2 and MSH6 (MSH6 has also been called GTBP or p160), binds to base-base mismatches and small ID heterologies and restores nick-directed repair on both types of substrate to extracts of cell lines that are genetically deficient in MSH2 (11, 14 -16) . 4 The affinity of MutS␣ for an oligonucleotide heteroduplex is markedly reduced in the presence of ATP (11) , an effect that has also been observed with bacterial MutS. In the case of the bacterial protein, this effect has been attributed to departure of the MutS dimer from the mismatch by translocation or linear diffusion along the DNA contour, with movement of the protein along the helix presumably involved in the search for the strand signal that directs repair (13) .
In addition to its ability to complex with MSH6, MSH2 also forms a heterodimer with a second MutS homolog called MSH3 (15, 16) . This MutS␤ complex binds to ID mispairs but displays little if any affinity for base-base mismatches. Furthermore, cell lines genetically defective in the MSH6 subunit of MutS␣ are deficient in base-base mismatch correction but retain partial activity on ID mispairs, and this residual activity has been shown to be due to the MutS␤ complex (11) . 4 MutS␣ thus functions in base-base and ID mismatch repair, but MutS␤ is apparently restricted to processing of the latter class of heterology. Whereas these findings may suggest redundant functions for MutS␣ and MutS␤ in the recognition and processing of ID mispairs, there is some evidence that MutS␣ and MutS␤ may function in a complementary fashion, differentially recognizing ID heterologies depending on size and sequence context (15) .
Recombinant MSH2 has also been reported to bind to mismatched base pairs (17) , but the heteroduplex affinity of this protein is considerably less than that of MutS␣ or MutS␤ (11, 14 -16) . Inasmuch as free MSH2 has not been detected during fractionation of human nuclear extracts 4 and since epistasis analysis suggests that Saccharomyces cerevisiae MSH2 functions in mitotic genetic stability only in conjunction with MSH3 or MSH6 (18, 19) , the biological function of free MSH2 must be regarded as uncertain.
A human MutL activity has been isolated by virtue of its ability to restore strand-specific mismatch repair to extracts of one class of hypermutable tumor cell line (20) . This activity, called MutL␣, is a heterodimer of the MutL homologs MLH1 and PMS2. Since cell lines deficient in MutL␣ are defective in repair of base-base and ID mismatches (8, 21) and since the MLH1⅐PMS2 heterodimer restores repair on both types of heterology (20) , MutL␣ presumably functions with MutS␣ in base-base mismatch repair or with either MutS␣ or MutS␤ in ID heterology repair. Although binding of MutL␣ to MutS␣⅐heteroduplex or MutS␤⅐heteroduplex complexes has not been demonstrated, defects in either MutL␣ or MutS␣ block mismatch correction at or prior to the excision stage of repair (8, 22) , consistent with function of both activities at an early step in repair. By contrast, S. cerevisiae MutL␣ has been shown to bind to complexes between MSH2 and heteroduplex or homoduplex DNA (23) , but this observation is subject to the caveat mentioned above concerning the functional significance of MSH2 in the absence of MSH6 or MSH3.
Other Activities Implicated in Eukaryotic
Strand-specific Mismatch Repair Proliferating cell nuclear antigen (PCNA), a required component of the eukaryotic replication apparatus, forms a homotrimeric sliding clamp around the helix and increases the processivity of DNA polymerases ␦ and ⑀ (24). Certain conditional S. cerevisiae PCNA mutants are hypermutable under permissive conditions, and epistasis analysis has indicated that this elevated mutability is due to participation of PCNA in a pathway that also depends on yeast MSH2, MLH1, and PMS1 (human PMS2 is a homolog of yeast PMS1) (25, 26) . Additional support for PCNA involvement in mismatch repair has been provided by the demonstration that yeast PCNA interacts physically with the MutS␤ heterodimer (26) and by two hybrid studies indicating interaction between yeast PCNA and yeast MLH1 or MSH2, and between human PCNA and human PMS2 (25) .
The role of PCNA as a DNA polymerase processivity factor might suggest that this protein is required during the repair synthesis stage of mismatch correction. While this possibility has not been excluded, the experiments of Umar et al. (25) indicate that PCNA, like MutS␣ and MutL␣, functions in repair at or prior to the excision step. Thus, nick-directed, mismatch-provoked excision in human cell extracts is inhibited by p21 WAF1 or by a p21 peptide that binds to PCNA and also inhibits PCNA-dependent DNA replication (27) . Involvement of PCNA in an early step of mismatch repair may indicate a role for the protein in the interaction of the mismatch and the strand signal and in loading of an excision system (25) or may indicate a special affiliation between the mismatch repair system and the replication apparatus, as has been suggested for the bacterial pathway (4). 1 The repair DNA synthesis step of mismatch repair in human extracts is blocked by aphidicolin (5-7) implicating DNA polymerase ␣, ␦, and/or ⑀ in the reaction. Extracts, depleted of pol ␦ but containing about 5% residual pol ⑀, and near normal amounts of pol ␣ have been shown to be proficient in mismatch-provoked excision but defective in the repair DNA synthesis step (28) . This defect is alleviated by pol ␦, implicating this DNA polymerase in the reaction. The presence of residual pol ␣ and pol ⑀ in the depleted extracts used in these experiments precludes conclusions concerning requirements for these activities, but they are clearly insufficient to support the repair synthesis step. In view of the role of PCNA in mismatch correction, it is noteworthy that this protein interacts with pol ␦ (29) and probably with pol ⑀ as well (30) .
Information concerning excision activities involved in mammalian mismatch repair is notably lacking. This step of the bacterial reaction depends on MutS, MutL, DNA helicase II, and depending on location of the strand break that directs correction, the 5Ј 3 3Ј single-stranded hydrolytic activity of RecJ or exonuclease VII or the 3Ј 3 5Ј single-stranded activity of exonuclease I (4). 1 Helicase or exonuclease involvement in human mismatch repair has not been reported, but hints concerning the nature of excision activities that may function in the eukaryotic reaction have been obtained in yeast. Mutations in the exoi gene of Schizosaccharomyces pombe, which encodes a 5Ј 3 3Ј exonuclease active on duplex DNA, are associated with an elevated mutation rate and marker effects during meiotic recombination that have been interpreted in terms of a mismatch repair defect (31) . Mutations in the S. cerevisiae RTH1 gene, which encodes a homolog of a mammalian 5Ј 3 3Ј exonuclease that has been implicated in lagging strand DNA synthesis (32), also confer a large increase in mutability (33) . Because mutation rates observed with rth1 msh2, rth1 mlh1, or rth1 pms1 double mutants are somewhat higher than those of strains harboring the single mutations, it has been suggested that RTH1 exonuclease participates in mismatch repair and in a second mutation avoidance pathway as well (33) , but other interpretations of these findings are also possible.
Mismatch Repair Defects and Tumor Development
Nowell (34) and Loeb et al. (35) proposed 20 years ago that genetic destabilization would predispose a cell to tumor development. Dramatic support for this idea has appeared during the past several years with the identification of a class of tumor cells that contain frequent mutations in microsatellite repeat sequences like (CA) n or (A) n . The microsatellite instability (MIN ϩ ) phenotype is characteristic of virtually all tumors that occur in individuals with hereditary nonpolyposis colon cancer (HNPCC) but is also relatively common in sporadic tumors occurring in a variety of tissues (36, 37) . 1 Current estimates indicate that at least 90% of affected individuals in HNPCC kindreds harbor heterozygotic defects in the genes encoding MLH1, MSH2, or PMS2 with mutations in the PMS2 locus accounting for only a minor fraction of affected families (1, 4, 36, 38) . 1 As might be anticipated from the heterozygotic mode of inheritance of the disease, unaffected cells in HNPCC individuals are typically MIN Ϫ and proficient in mismatch repair, whereas the MIN ϩ phenotype of tumor cells is attributable to inactivation of the wild type allele of the repair gene in question and loss of mismatch repair proficiency. The association of mismatch repair defects with the MIN ϩ phenotype of sporadic tumors has been less thoroughly studied, but defects in both copies of the MLH1, MSH2, PMS2, or MSH6 genes have been identified in a number of cases. For example, mismatch repair mutations have been identified in about 65% of the MIN ϩ sporadic colon tumors that have been examined (38) , 1 but a screen of sporadic MIN ϩ endometrial tumors failed to identify mutations in genes encoding components of the MutS␣ or MutL␣ heterodimers (39) . By contrast, in vitro assay of extracts prepared from a relatively large set of MIN ϩ tumor cell lines derived from a variety of tissues has yielded a perfect correlation between microsatellite instability and mismatch repair deficiency, which in nearly all cases was attributable to biochemical deficiency of MutS␣ or MutL␣ (8, 9, 11, 21, 40 -42) . This set includes lines derived from both inherited and sporadic tumors, as well as several that apparently lack mutations within the structural genes that encode these repair activities. While defects in other repair or mutation avoidance systems may well confer a MIN ϩ phenotype, these in vitro findings suggest that epigenetic effects or as yet unidentified regulatory mutations may confer mismatch repair deficiency and microsatellite instability. Indeed, Kolodner and colleagues (43) have recently obtained evidence for epigenetic shutdown of MLH1 expression in several sporadic MIN ϩ colon tumors. Inactivation of the mismatch repair system in MIN ϩ tumor cells results in a dramatic genetic destabilization as judged by analysis of several established cell lines in culture (44 -46) . Mutation rates scored either at microsatellite repeat sequences or at the HPRT locus are 100 -1,000 times higher in these lines than in repairproficient cells, with the HPRT mutation spectrum including frameshifts, transitions, and transversions (41, 44, 47) . This large increase in mutability presumably predisposes repair-deficient cells to tumor development by greatly increasing the probability of the occurrence of mutations that circumvent cell growth control.
Human MutS␣ and MutL␣ as Sensors of
Genetic Damage The nature of mutations that occur in microsatellite sequences or at the HPRT gene in MIN ϩ tumor cells is consistent with an origin as DNA biosynthetic errors, implicating mammalian mismatch repair in replication fidelity. As in bacteria (2), the mammalian repair system may also act as a barrier to recombination between DNA elements that have diverged at the sequence level (48) . Although the mechanism of this recombination effect is uncertain, it presumably involves recognition of mismatches within the recombination heteroduplex produced by strand transfer between related but nonidentical sequences. In addition to its function in reversal of replication and recombination errors that occur during the course of chromosome metabolism, the human mismatch repair system also plays an important role in the cellular response to certain types of DNA damage.
N-Methyl-NЈ-nitro-N-nitrosoguanidine (MNNG) and N-methyl-N-nitrosourea (MNU) are mutagenic and cytotoxic DNA methylating agents, with both activities attributable to production of O 6 -methylguanine (O 6 meG) (49) . In vitro selection for resistance to the cytotoxic effects of these agents has yielded several types of resistant mutants. The major class is characterized by the ability to tolerate O 6 meG lesions that are cytotoxic to parental cells, hypermutability in the absence of MNNG or MNU, a G2 checkpoint defect upon challenge with a DNA-methylating agent, and crossresistance to the cytotoxic effects of the base analogue 6-thioguanine (50 -52) . Analysis of several such methylation-tolerant cell lines has revealed a deficiency of MutS␣, with the defect in one case localized to the MSH6 subunit (11, 22, 53) . Conversely, mouse ES cells homozygous for a MSH2 knockout mutation (48) and a MIN ϩ colorectal tumor cell line deficient in MLH1 are resistant to the cytotoxic effects of MNNG, with sensitivity to the agent in the case of the latter cell line restored upon introduction of chromosome 3 carrying a wild type copy of the MLH1 gene (54) . Like the methylation-tolerant cell lines mentioned above, the MLH1-deficient tumor cell line displays a G2 checkpoint defect upon exposure to 6-thioguanine (55) . Genetic defects in MSH2, MSH6, or MLH1 therefore appear to be sufficient to confer tolerance to DNA lesions produced by MNNG, MNU, or 6-thioguanine, but exceptions to this generalization may exist (56) .
Similar results have been obtained with a subset of tumor cell lines isolated in vitro by single-step selection for resistance to cisplatin, a widely used chemotherapeutic agent. Concomitant loss of mismatch repair proficiency with selection for cisplatin resistance has been reported for several ovarian tumor cell lines, with repair deficiency in each case attributable to defects in MutL␣ (56, 57) . Furthermore, one of these drug-resistant lines has been shown to be defective in activation of G1 and G2 checkpoint responses upon cisplatin exposure (58) . MSH2-or MLH1-deficient colon and endometrial tumor cell lines with no previous cisplatin exposure history have also been shown to be significantly more resistant to the cytotoxic effects of the drug than repair-proficient cell lines (56) , but there are indications that the degree of cisplatin resistance conferred by a mismatch repair defect may also depend on other genetic factors, such as status of the p53 locus (57) .
These in vitro observations are of interest in view of the wide use of DNA methylators and cisplatin in chemotherapy, but clinical reports of co-selection for drug resistance and mismatch repair deficiency are lacking. Nevertheless, recent findings with a human glioblastoma multiforme maintained as a xenograft in athymic nude mice suggest that such reports may be forthcoming. Serial in vivo treatment of the xenograft with procarbazine, which is metabolically activated to yield a DNA methylator, resulted in procarbazine resistance and concomitant failure to express MSH2, with the tumor displaying cross-resistance to MNU, temozolomide, and busulfan (59) .
The association of mismatch repair defects with drug resistance implies that MutS␣ and MutL␣ are involved in triggering the cytotoxic response to DNA methylators and cisplatin, although the molecular events involved in this response have not been established. However, the role of the proteins in this process appears to be direct since MutS␣ specifically recognizes lesions containing O 6 meG and the cytotoxic 1,2-intrastrand d(GpG) cross-link produced by cisplatin but fails to recognize the 1,3-intrastrand adduct produced by transplatin, a compound of limited cytotoxicity that lacks chemotherapeutic activity (60, 61) . Recombinant MSH2 protein has also been found to bind weakly to cisplatin adducts (62) .
The simplest interpretation of these findings is that recognition of certain DNA lesions by MutS␣ initiates a sequence of events that may lead to cell death. Two hypothetical mechanisms by which this might occur are summarized in Fig. 2 . One model attributes killing to translesion synthesis when the replication fork encounters a damaged nucleotide in the template strand (50) . The presence of the resulting base pair anomaly triggers mismatch repair, but since action of this system is restricted to the daughter DNA strand, the offending lesion persists in the template. The ensuing abortive turnover of new DNA is postulated to result in a death response. In the second model, lesion recognition by MutS␣ and MutL␣ leads to a checkpoint response or at high lesion load, cell death by more a direct interaction with the regulatory systems involved, without proceeding through the excision pathway involved in the processing of DNA biosynthetic errors (60, 62) . It is 
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intriguing to consider such mechanisms in view of evidence cited above indicating participation of PCNA at an early step in the repair reaction and physical interaction of the protein with Mut complexes (25) . In addition to its interaction with human PMS2, PCNA also interacts with the p21 inhibitor of cyclin-dependent kinases and forms a quaternary complex with p21, a cyclin, and a cyclin-dependent kinase (27) . While involvement of the mismatch repair system in the response to DNA damage is of interest in terms of the cell cycle regulation and initiation of an apoptotic response to genetic lesions, the phenomenon may also have significant clinical ramifications. The resistance of repair-defective cells to DNA methylators and cisplatin raises questions concerning appropriate chemotherapeutic regimens for treatment of MIN ϩ tumors. Furthermore, given the propensity of these agents to select for mismatch repair mutations and the predisposition of repair-deficient cells to tumor development, the use of such agents may result in the induction of secondary cancers.
